Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
about
Quantum chemical analysis of the deferiprone-iron binding reactionEfficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromesWorld health dilemmas: Orphan and rare diseases, orphan drugs and orphan patientsPhytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical PathologyIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesHydrops fetalis caused by homozygous alpha-thalassemia and Rh antigen alloimmunization: report of a survivor and literature reviewRenal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective studyThe oral iron chelator deferiprone protects against iron overload-induced retinal degenerationEDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retinaTherapeutic potential of iron chelators in diseases associated with iron mismanagement.Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.New developments and controversies in iron metabolism and iron chelation therapy.UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis.Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases.Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.Quality of Life Outcomes in a Pediatric Thalassemia Population in Egypt.Safety profiles of iron chelators in young patients with haemoglobinopathies.Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromesEffect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease.In vitro studies of 3-hydroxy-4-pyridinones and their glycosylated derivatives as potential agents for Alzheimer's disease.Agranulocyosis in Beta Thalassemia Major Patients treated with Oral Iron Chelating Agent (Deferiprone).The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.New chelation therapies and emerging chelating drugs for the treatment of iron overload.Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients.Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin.
P2860
Q24657275-A50BBC5F-3061-4FEB-B2F7-C3421C446A8FQ26764818-94527AD6-031E-4902-AC63-6C20654B417EQ26826936-FFB7A6C0-90B0-4871-B0DF-2FED9B553166Q26863390-114E3179-8DAB-42C3-960C-2A3E22FAD525Q28388335-453EE057-3EC2-4AD7-8640-70E0FC780381Q33723565-04D1FE91-12A7-451E-8BEC-A94E3647D5A5Q33948705-3F8D009A-B5C3-447E-A93C-1ADA930FFAAAQ34281402-78DF114D-B25A-44CB-B7F4-F3059E5A30E7Q34642777-6CF77A3E-FBEF-4CF9-AFA2-A01C70C0165BQ34761250-5305412A-4F27-4D6E-AF05-2504B27B2F23Q36050418-01EB3DFE-1193-4CA1-990B-A840A2E916ABQ36461028-00F035E6-2791-45E5-A843-6F9DDF997675Q36518457-59CED3EB-F782-48B6-A0AD-18776E7EB4FAQ36518462-C06A6BAA-0915-4A2C-938F-402167255E90Q36719376-9A7583F5-237F-4885-83F0-53E6722884A7Q36792667-C73CB23F-FF65-4DF9-B3BE-E26B55FBECD1Q37084711-97901D0E-8C32-43B1-BF99-FB2A702CB3E7Q37084735-498134FC-656F-4467-A024-0AD86E8F867AQ37114840-93E5EAA8-53B8-47DE-BA6D-AE2894900BC1Q37376532-D123E86A-AE27-4DB8-A502-C4A2A8F4A91BQ37765561-3D9DE6AA-AFCA-44D6-A69B-4EEBC3BC2A02Q38074340-EC926790-E714-461B-A562-3EDF9EB06C17Q38099045-E5B517B0-6A36-49D2-B409-9A05198C67DDQ38821391-3B5B51A6-D661-46AB-BB90-EB5230714A7FQ39022073-F5B03DA2-9053-4800-8A1C-809CF724D9D6Q39453693-882B85F9-038B-4A5E-85C8-94AF99B37E98Q39552627-8AAA7B2D-9211-41B6-B7D2-399343F3052FQ39747442-5C9012C1-B0EE-4ED1-BCC9-3FA9E7E9E157Q40901148-ECDCDC69-FBD6-4224-893E-61E30C75E153Q43044189-27C8BA03-7B9C-4C4F-8EDA-C24948618631Q43199274-0572FA8D-1FFD-4AC1-A779-6F9F222006B5Q46057410-8AA401C2-48CD-476D-8AA0-D26A7DDAA207Q46753935-CD9E4EBF-67AF-461E-B469-66C37E89515BQ46965074-A0FEA120-CA39-4019-B3A1-7781E6117F03Q51173696-FA9EC546-FF87-4A7B-A5A5-EB1E50BC899DQ51305717-A1C55778-57D0-45CC-B5F1-8AF736C1A584Q51798516-3C73C772-4CB8-4462-88F5-C59703AE3FDAQ52573930-47F2A119-3303-4B59-801A-8EA3DB2DBC84
P2860
Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Benefits and risks of deferipr ...... tic aspects with deferoxamine.
@ast
Benefits and risks of deferipr ...... tic aspects with deferoxamine.
@en
Benefits and risks of deferipr ...... tic aspects with deferoxamine.
@nl
type
label
Benefits and risks of deferipr ...... tic aspects with deferoxamine.
@ast
Benefits and risks of deferipr ...... tic aspects with deferoxamine.
@en
Benefits and risks of deferipr ...... tic aspects with deferoxamine.
@nl
prefLabel
Benefits and risks of deferipr ...... tic aspects with deferoxamine.
@ast
Benefits and risks of deferipr ...... tic aspects with deferoxamine.
@en
Benefits and risks of deferipr ...... tic aspects with deferoxamine.
@nl
P2093
P1433
P1476
Benefits and risks of deferipr ...... tic aspects with deferoxamine.
@en
P2093
Annita Kolnagou
George J Kontoghiorghes
Katia Neocleous
P304
P356
10.2165/00002018-200326080-00003
P577
2003-01-01T00:00:00Z
P6179
1045114336